MarketPulse

Aldeyra Therapeutics

12 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

ALDX Securities Lawsuit Deadline Looms: Rosen Law Targets $100K+ Loss Investors

ALDX investors face May 29, 2026 deadline to join securities class action over alleged reproxalap clinical trial misstatements. Rosen Law targets shareholders with $100K+ losses.
ALDXinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Aldeyra Therapeutics Faces Securities Class Action Over Clinical Trial Disclosures

Rosen Law Firm seeks lead plaintiffs in securities class action against Aldeyra Therapeutics over alleged reproxalap trial misstatements. Deadline: May 29, 2026.
ALDXsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··The Schall Law Firm

Aldeyra Therapeutics Faces Class Action Over Reproxalap Drug Claims

Schall Law Firm seeks $ALDX investors for securities fraud lawsuit alleging Aldeyra Therapeutics made false reproxalap drug claims between November 2023-March 2026.
ALDXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Trip.com Faces Securities Class Action Over Alleged Regulatory Misstatements

Rosen Law Firm filed securities class action against Trip.com over alleged false statements on regulatory risks. Investors have until May 11, 2026 to become lead plaintiffs.
TCOMSLNOALDXregulatory risksecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Aldeyra Securities Suit Eyes May Deadline as Trial Lawyers Urge Investors to Act

Rosen Law Firm reminds $ALDX investors of May 29, 2026 deadline to join securities class action alleging false reproxalap trial disclosures.
ALDXsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Rosen Law Firm Files Securities Class Action Against $TCOM, Urges Investors to Act Before May 2026

Rosen Law Firm files securities class action against Trip.com Group Limited ($TCOM), urging investors with losses exceeding $100K to secure counsel before May 11, 2026 deadline.
ALITTCOMALDXinvestor lossesregulatory risk
GlobeNewswire Inc.GlobeNewswire Inc.··The Schall Law Firm

Aldeyra Therapeutics Faces Class Action Over Reproxalap Drug Claims

Schall Law Firm mobilizes class action against Aldeyra Therapeutics for alleged securities fraud tied to reproxalap drug claims. Eligible investors must participate by May 29, 2026.
ALDXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Aldeyra Therapeutics Faces Securities Lawsuit Over Reproxalap Trial Claims

Rosen Law Firm sues Aldeyra Therapeutics for false reproxalap trial claims. Lead plaintiff deadline: May 29, 2026.
ALDXsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Robbins Llp

Aldeyra Therapeutics Hit with Class Action Over Failed Drug; Stock Plummets 70%

Robbins LLP sued Aldeyra Therapeutics over alleged investor misrepresentation regarding failed drug reproxalap. FDA rejected approval; stock fell 70.7%. Lead plaintiff deadline: May 29, 2026.
ALDXclass action lawsuitlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··The Schall Law Firm

Aldeyra Therapeutics Faces Securities Fraud Class Action Over Reproxalap Claims

Schall Law Firm launches class action against $ALDX over alleged false statements regarding reproxalap drug candidate. Investors who bought securities Nov 2023-Mar 2026 can join before May 29 deadline.
ALDXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Aldeyra Therapeutics Faces Securities Class Action Over Reproxalap Trial Disclosures

Rosen Law Firm files securities class action against $ALDX over alleged misleading statements regarding reproxalap clinical trial results. Lead plaintiff deadline set for May 29, 2026.
ALDXsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

ImmunityBio Faces Securities Class Action Over Anktiva Misrepresentations

Rosen Law Firm files class action against $IBRX, alleging founder Patrick Soon-Shiong overstated Anktiva capabilities, misleading investors about company prospects.
IBRXSLNOALDXsecurities fraudclass action lawsuit